USFDA concludes inspection at Gland Pharma with zero observations

The inspection concluded with zero observations on Form 483 and a classification of No Action Indicated (NAI).

128
USFDA Inspection
USFDA Inspection

Last Updated on November 11, 2024 by The Health Master

The Gland Pharma received a zero-observation certificate on Form 483 from the United States Food and Drug Administration (USFDA) for its Visakhapatnam facility.

The USFDA conducted the good manufacturing practice (GMP) inspection at the company’s VSEZ Sterile Oncology facility at Visakhapatnam between July 20 and July 28.

The inspection concluded with zero observations on Form 483 and a classification of No Action Indicated (NAI).

On July 14, the company received one observation after the USFDA conducted a GMP inspection at Dundigal facility at Hyderabad during July 3-14. 

The regulator had last month issued one observation on the company’s Pashamylaram facility at Hyderabad after GMP and pre-approval inspection (PAI) for seven products.

Understanding GMP, cGMP, and WHO-GMP

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news